Skip to content
lifestyle.floredechampagne.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Revolution Medicines, Inc.
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
August 26, 2026
Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
August 19, 2026
Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026
August 18, 2026
Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
May 31, 2026
Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation
May 21, 2026
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
May 6, 2026
Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress
May 6, 2026
Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026
April 29, 2026
Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting
April 21, 2026
Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting
April 21, 2026
1
2
Next Page
→